Preclinical studies reveal MLN4924 is a promising new retinoblastoma therapy

RB1 loss (RB1(null)) or MYCN amplification (MYCN(amp)) in fetal human retina causes retinoblastoma. SKP2 loss kills RB1(null) cells, but small molecule SKP2 inhibitors remain unexplored therapeutically. Whether SKP2 is synthetic lethal in MYCN(amp) retinoblastoma is unclear. SKP2 is the substrate re...

Descripción completa

Detalles Bibliográficos
Autores principales: Aubry, Arthur, Yu, Tao, Bremner, Rod
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026052/
https://www.ncbi.nlm.nih.gov/pubmed/32123578
http://dx.doi.org/10.1038/s41420-020-0237-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7026052/
https://www.ncbi.nlm.nih.gov/pubmed/32123578
http://dx.doi.org/10.1038/s41420-020-0237-8

Ejemplares similares